Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pregabalin adjunctive therapy for children with autism spectrum disorder
IRCT20090117001556N161Phase 3Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Pregabalin + risperidone with Placebo + risperidone (2 arms). Primary endpoint: Severity of autism symptoms. Started May 2025; status: recruiting.
02
Drugs
pregabalin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on IRCT20090117001556N161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090117001556N161.